Guide

Debarment vs. disqualification

The two most serious marks on a clinical investigator’s FDA record are routinely confused, and the confusion matters: they have different triggers, different processes, and different consequences for a sponsor. A person can be on either list, on both, or — most often, even when there is a real problem — on neither.

Disqualification: FDA’s administrative remedy

Disqualification (21 CFR 312.70 for drugs and biologics) is an administrative process FDA runs itself. It targets a clinical investigator who has repeatedly or deliberately failed to comply with the regulations, or has submitted false information to FDA or to a sponsor. The process starts with a NIDPOE letter, gives the investigator a chance to explain and then a formal hearing, and can end three ways: proceedings terminated, a consent agreement with restrictions or assurances, or full disqualification. In the words of 21 CFR 312.70(b), a disqualified clinical investigator is “not eligible to receive test articles” and is “ineligible to conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA”.

Debarment: the statutory bar

Debarment comes from statute — section 306 of the Food, Drug, and Cosmetic Act — and generally follows a criminal conviction connected to the regulation of drug products. For individuals convicted of a relevant felony, debarment is mandatory and permanent. A debarred person may not provide services in any capacity to a firm with an approved or pending drug application — not as a clinical investigator, not as a consultant, not as anything. Applicants certify to FDA that no debarred person provided services in connection with their application, and knowingly using one carries penalties for the firm, which is what makes debarment screening a standing obligation rather than a one-time courtesy check.

Side by side

Trigger. Disqualification: repeated or deliberate regulatory violations, or false information — established administratively. Debarment: a criminal conviction.

Scope. Disqualification: eligibility to conduct investigational research. Debarment: providing services in any capacity to drug application holders.

Duration. Disqualification: until FDA reinstates the clinical investigator (possible on adequate assurances). Debarment: permanent for felony convictions; time-limited in some other cases.

Sponsor obligation. Disqualification: don’t select an ineligible clinical investigator. Debarment: certify — on penalty — that no debarred person touched the application.

Why vetting checks both — and then keeps reading

Both lists are small. The overwhelming majority of clinical investigators with troubling FDA history appear on neither: their record lives in inspection findings and warning letters that never escalated to proceedings. That is why clinical investigator vetting treats the lists as the last rung of a ladder — and reads the inspection record underneath them, where the early signals actually are.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.